查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631145

异位性皮肤炎治疗药物市场规模、份额、趋势分析报告：按药物类别、给药途径、分销管道、地区、细分市场预测，2025-2030年

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids. Biologics), By Route Of Administration (Topical, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

异位性皮肤炎治疗药物市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球异位性皮肤炎治疗市场预计将达到298.8亿美元。

预计2025年至2030年复合年增长率为9.02%。由于全球异位性皮肤炎盛行率不断上升、认识不断提高以及对治疗的高需求等因素，异位性皮肤炎（AD）治疗市场预计将出现成长机会。此外，不断推出创新产品占领市场，是企业赢得市场占有率、维持主导地位的关键策略。

越来越多的高效且副作用较少的产品正在研发中，预计将推动市场的发展。例如，预计2020年至2029年间将有11种治疗异位性皮肤炎的新药上市。其中包括以下药物类别： Janus激酶 (JAK) 抑制剂、磷酸二酯酶-4 (PDE-4) 和白细胞介素-4&-13 (IL-4/13)。这些新药的推出将改善重度和中度 AD 患者的生活品质并扩大治疗选择。

简审类等监管支持预计将加速 AD 的研究和开发。例如，Demira 的 lebrikizumab 获得了简审类。此外，2020 年 10 月，Forte Biosciences, Inc. 的药物 FB-401 获得 FDA 的简审类。因此，公司对研发的兴趣增加预计将推动市场成长。

增加资金和积极主动的政府倡议来研究和开发异位性皮肤炎新治疗方法将支持该地区的成长。公共和私人组织之间的合作预计将提高世界各地消费者的意识。例如，2022年6月，大冢製药株式会社（大冢控股）宣布在日本推出AD治疗药物Moiselt软膏（通用名：difamilast）。该药是一种非类固醇外用磷酸二酯酶 4 型抑制剂。

在日本，日本皮肤病学会 (JDA) 制定了 AD 指南。该指南于2020年进行了修订，不仅规定了诊断标准，还规定了治疗方法。例如，与发炎相关的 AD 可采用外用皮质类固醇和Tacrolimus治疗。这使得更容易系统地治疗患者并提高治疗效果。

特应性皮肤炎治疗药物市场报告亮点

  • 生技药品领域占市场主导地位，2024年占全球销售额的38.07%。由于高功效、产品核可增加以及针对异位性皮肤炎的强大生物生物製药管道的可用性，对生物製药的需求增加推动了生物製药行业的成长。
  • 外用药物细分市场占据主导地位，2024 年市场占有率为 39.73%。除了局部治疗的安全性和有效性外，其高处方率和实惠的价格也对其广泛使用做出了重大贡献。
  • 2024年，医院药局细分市场占61.11%的重要市场占有率。许多患有中度至重度异位性皮肤炎的患者需要处方笺药，这些药物通常在医院药房更容易买到。
  • 2024年北美异位性皮肤炎治疗市场占45.12%。这是由于生物製药和局部治疗的高采用率。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 异位性皮肤炎治疗药物市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 异位性皮肤炎治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章 异位性皮肤炎治疗药物市场：依药物类别估计与趋势分析

  • 全球异位性皮肤炎药物市场：按药物类别分類的仪表板
  • 全球异位性皮肤炎治疗药物市场：依药物类别波动分析
  • 按药品类别分類的收益
  • 皮质类固醇
  • Calcineurin抑制剂
  • PDE4抑制剂
  • 生物製药
  • 其他的

第五章 异位性皮肤炎治疗药物市场：依给药途径估计与趋势分析

  • 全球异位性皮肤炎药物市场：按给药途径分類的仪表板
  • 全球异位性皮肤炎治疗药物市场：依给药途径波动分析
  • 按管理途径分類的收益
  • 局部的
  • 胃肠外的
  • 口服

第六章 异位性皮肤炎治疗药物市场：依分销管道估算与趋势分析

  • 全球异位性皮肤炎治疗药物市场：按分销管道分類的仪表板
  • 全球异位性皮肤炎治疗药物市场：按分销管道波动分析
  • 按分销管道分類的收益
  • 医院药房
  • 零售药房
  • 其他药局

第七章 异位性皮肤炎治疗药物市场：区域估计与趋势分析

  • 区域仪表板
  • 市场规模、预测与趋势分析（2018-2030）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Pfizer Inc.
    • Sanofi
    • AbbVie Inc.
    • GALDERMA LABORATORIES, LP
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • LEO Pharma Inc.
    • Otsuka Pharmaceutical Co., Ltd
    • Novartis AG
    • Incyte Corporation
Product Code: GVR-2-68038-546-5

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 29.88 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.02% from 2025 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

  • The biologics segment dominated the market and accounted for 38.07% of the global revenue in 2024. The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and availability of a robust pipeline of biologic drugs for atopic dermatitis.
  • Topical segment dominated the market with a market share of 39.73% in 2024. The high prescription rates and affordability of medications, combined with the safety and efficacy of topical treatments, contribute significantly to their widespread use.
  • The hospital pharmacies segment held a considerable market share of 61.11% in 2024. Many patients with moderate to severe atopic dermatitis require prescription medications, which are often more readily available through hospital pharmacies.
  • The North America atopic dermatitis drugs market accounted for 45.12% share in 2024. This can be attributed to the high adoption rates of biologics and topical treatments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Route of Administration outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of atopic dermatitis
      • 3.2.1.2. Rising awareness about disease
      • 3.2.1.3. Technological advancement
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations pertaining to drug approval
  • 3.3. Atopic Dermatitis Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Atopic Dermatitis Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Atopic Dermatitis Drugs Market: Drug Class Dashboard
  • 4.2. Global Atopic Dermatitis Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Atopic Dermatitis Drugs Market By Drug Class, Revenue
  • 4.4. Corticosteroids
    • 4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Calcineurin Inhibitors
    • 4.5.1. Calcineurin Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. PDE4 Inhibitors
    • 4.6.1. PDE4 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Biologics
    • 4.7.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Atopic Dermatitis Drugs Market: Route of Administration Dashboard
  • 5.2. Global Atopic Dermatitis Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Topical
    • 5.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Parenteral
    • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oral
    • 5.6.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Atopic Dermatitis Drugs Market: Distribution Channel Dashboard
  • 6.2. Global Atopic Dermatitis Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Pfizer Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Sanofi
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. AbbVie Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GALDERMA LABORATORIES, L.P.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Eli Lilly and Company
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Regeneron Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. LEO Pharma Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Otsuka Pharmaceutical Co., Ltd
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Novartis AG
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Incyte Corporation
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Europe atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 Germany atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 UK atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 France atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Italy atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Spain atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Sweden atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 Aisa Pacific atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 China atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Japan atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 India atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 South Korea atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Australia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 Australia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Australia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 65 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Latin America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 68 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Argentina atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 MEA atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 76 MEA atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 MEA atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 South Africa atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 UAE atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Kuwait atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Atopic dermatitis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Atopic dermatitis drugs market segment snapshot
  • Fig. 10 Atopic dermatitis drugs market competitive snapshot
  • Fig. 11 Atopic dermatitis drugs market driver impact
  • Fig. 12 Atopic Dermatitis Drugs market restraint impact
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Value chain analysis
  • Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
  • Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
  • Fig. 18 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Calcineurin Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 PDE4 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Atopic Dermatitis Drugs market: Route of administration outlook and key takeaways
  • Fig. 24 Atopic Dermatitis Drugs market: Route of administration movement analysis
  • Fig. 25 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Atopic Dermatitis Drugs market: Distribution channel outlook and key takeaways
  • Fig. 29 Atopic Dermatitis Drugs market: Distribution channel movement analysis
  • Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Global Atopic Dermatitis Drugs market: Regional movement analysis
  • Fig. 34 Global Atopic Dermatitis Drugs market: Regional outlook and key takeaways
  • Fig. 35 Global Atopic Dermatitis Drugs market share and leading players
  • Fig. 36 North America, by country
  • Fig. 37 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. key country dynamics
  • Fig. 39 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada key country dynamics
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico key country dynamics
  • Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Argentina key country dynamics
  • Fig. 78 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 South Africa key country dynamics
  • Fig. 81 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia key country dynamics
  • Fig. 83 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 UAE key country dynamics
  • Fig. 85 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait key country dynamics
  • Fig. 87 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Market share Analysis of key market players, 2024